Article Text


PTH-105 The Effect of Infliximab Pre-Treated Human Blood-Enriched Dendritic Cells from Patients with Active Crohn’S Disease and Healthy Controls on Subsequent Human T-Lymphocyte Phenotype and Cytokine Production in Vitro
  1. S T C Peake1,
  2. D Bernardo2,
  3. E Mann2,
  4. J Landy1,
  5. H Omar2,
  6. S C Knight2,
  7. A L Hart1
  1. 1IBD Unit, St Mark’s Hospital
  2. 2APRG, Imperial College, London, UK


Introduction Dendritic cells (DC) play a key role in discriminating between commensal microorganisms and potentially harmful pathogens. Expression of surface markers and cytokine production by DC at the time of antigen presentation control T-cell differentiation, cytokine profile & homing properties imprinted on stimulated T-cells. This process defines the type of immune response that occurs and its anatomical location. In CD, dysregulation of the immune response to gut microbiota and aberrant immune cell trafficking play a central role in disease pathogenesis. Infliximab (IFX) is an effective treatment for CD, but its mechanism of action is unclear. In this study, we investigated the effect of IFX pre-treated blood-enriched DC, isolated from patients with active CD and healthy controls (HC), on human T-cell proliferation, phenotype&cytokine production

Methods Low density cells (LDC), enriched for DC, were obtained following Ficoll and Nycoprep gradient separation of fresh blood from patients with active ileocolonic CD (CDAI > 220) and HC. LDC were cultured (0.5x106cells/ml) with IFX (1.10μg&100μg/ml&basal) for 24hr. T-cells were enriched from allogeneic HC blood and labelled with CFSE. LDC were added to T-cells in complete medium (400,000cells/ml) at basal,1.2&3% concentrations and incubated for 5days. Following incubation, T-cell proliferation, expression of β7&CLA surface homing markers and cytokine content of T-cells (TNFα, TGFβ, IFNγ, IL-10.15.17) was quantified by flow cytometry on stimulated T-cells. Unparied t-test and one-way ANOVA statistical analyses were applied

Results In basal conditions, LDC from HC & CD patients did not differ in their stimulatory capacity for allogeneic T-cells or in the cytokine profile acquired by T-cells. However, T-cells stimulated by LDC from CD patients decreased β7 intensity ratio. Following culture with IFX, LDC decreased their stimulatory capacity in a dose-dependent, stepwise fashion in both HC and CD. Culture with IFX did not have any effect on the acquired homing profile of stimulated T-cells, although these T-cells had a trend (not statistically significant) towards lower TNFα and higher IL-17 production

Conclusion The marked reduction in the ability of LDC to stimulate T-cells following culture with IFX represents one plausible explanation for the efficacy of anti TNF-alpha therapies in the treatment of CD. This effect was dose-dependent (within our range of test concentrations) suggesting that higher doses of IFX further reduce T-cell stimulation and may provide one explanation of the clinical benefits of dose escalation in refractory CD

Disclosure of Interest None Declared.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.